Latest research on Rosuvastatin

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Rosuvastatin and alcohol

Four (57.1%) of the reviews observed at the efficacy of medicines such as of statins (LOVASTATIN, Atorvastatin, Simvastatin, Pravastatin, Rosuvastatin, and Fluvastatin),47 Ursodeoxycholic acid,48 probiotics,49 and Pentoxifylline,50 and one (14.3%) compared the benefits and harms of herbal medicines in NAFLD/AFLD (alcoholic fatty liver disease) patients. [source, 2014]
The plasma concentrations of Rosuvastatin were modestly increased in patients with chronic alcoholic liver disease.18 [source, 2013]
Thus, the aim of the present study was to evaluate whether Rosuvastatin modulates the carbohydrate and lipid metabolism, the level of non-alcoholic fatty liver disease (NAFLD), and the body mass gain in a model of diet-induced obesity. [source, 2013]